D
WPD Pharmaceuticals Inc. WBIO
CNSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
D
Sell 9/9/2024Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 9/9/2024 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.001 to -$0.0001, operating cash flow increased 89.75% from -$55.6 to -$5.7, and EBIT increased 16.43% from -$71.2 to -$59.5.
E
Sell 8/7/2024Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D- on 8/7/2024 due to a decline in the total return index, volatility index and growth index.
D
Sell 7/23/2024Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 7/23/2024 due to an increase in the volatility index and total return index.
E
Sell 7/8/2024Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D- on 7/8/2024 due to a noticeable decline in the total return index and volatility index.
D
Sell 6/7/2024Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 6/7/2024 due to a noticeable increase in the efficiency index, valuation index and volatility index.
E
Sell 5/24/2024Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to E+ from E- on 5/24/2024 due to a noticeable increase in the growth index, total return index and solvency index. Operating cash flow increased 43.71% from -$60.4 to -$34, and EBIT increased 9.74% from -$54.4 to -$49.1.
E
Sell 2/6/2024Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E- from D- on 2/6/2024 due to a substantial decline in the growth index, solvency index and valuation index. Operating cash flow declined 292.21% from -$15.4 to -$60.4, earnings per share declined from -$0.0002 to -$0.0005, and EBIT declined 135.5% from -$23.1 to -$54.4.
D
Sell 12/16/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 12/16/2022 due to a decline in the volatility index.
D
Sell 11/9/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 11/9/2022 due to an increase in the volatility index and total return index.
D
Sell 10/20/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 10/20/2022 due to a decline in the volatility index.
D
Sell 10/5/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 10/5/2022 due to an increase in the volatility index and total return index.
D
Sell 9/15/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 9/15/2022 due to a decline in the volatility index and total return index.
D
Sell 8/30/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 8/30/2022 due to an increase in the volatility index and total return index.
D
Sell 8/10/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 8/10/2022 due to a decline in the volatility index.
D
Sell 7/26/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 7/26/2022 due to an increase in the volatility index.
D
Sell 7/7/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 7/7/2022 due to a decline in the volatility index and total return index.
D
Sell 6/22/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 6/22/2022 due to an increase in the volatility index and valuation index.
D
Sell 6/6/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 6/6/2022 due to a decline in the volatility index and total return index.
D
Sell 5/19/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from E+ on 5/19/2022 due to an increase in the volatility index.
E
Sell 5/13/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell 5/4/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell 5/1/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell 4/21/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell 4/20/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D on 04/20/2022.
D
Sell 4/19/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 4/19/2022 due to an increase in the total return index and volatility index.
D
Sell 3/31/2022Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 3/31/2022 due to a decline in the total return index.
D
Sell 3/15/2022Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 3/15/2022 due to an increase in the total return index and growth index. Earnings per share increased from -$0.0088 to -$0.005, and EBIT increased 20.8% from -$1.1M to -$870.3.
D
Sell 11/23/2021Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 11/23/2021.
E
Sell 11/8/2021Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index, volatility index and valuation index.
D
Sell 9/17/2021Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to D- from D on 9/17/2021 due to a decline in the volatility index and total return index.
D
Sell 9/2/2021Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D from D- on 9/2/2021 due to an increase in the valuation index and growth index. EBIT increased 35.39% from -$1.7M to -$1.1M, and operating cash flow increased 28.93% from -$125.8 to -$89.4.
D
Sell 5/11/2021Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 5/11/2021 due to an increase in the volatility index and valuation index.
E
Sell 4/26/2021Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D- on 4/26/2021 due to a decline in the volatility index.
D
Sell 4/9/2021Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 4/9/2021 due to an increase in the volatility index and valuation index.
E
Sell 3/25/2021Downgrade
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from D- on 3/25/2021 due to a decline in the volatility index.
D
Sell 3/10/2021Upgraded
WPD Pharmaceuticals Inc. (WBIO) was upgraded to D- from E+ on 3/10/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 140.81% from $232.3 to $559.4, earnings per share increased from -$0.0144 to -$0.0084, and EBIT increased 32.85% from -$1.7M to -$1.14M.
E
Sell 10/16/2020None
WPD Pharmaceuticals Inc. (WBIO) was downgraded to E+ from U on 10/16/2020.
Weiss Ratings